ScottRobertSolomonMD

Hematology • Atlanta, GA

Myeloproliferative Disorder Hematology-Oncology

Physician

Join to view full profile

Dr. Solomon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Solomon's full profile

Already have an account?

Office
5670 Peachtree Dunwoody Rd
Ste 1000
Atlanta, GA 30342
Phone+1 404-255-1930

Fax+1 404-459-8510

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1998 - 2001
University of California (San Francisco)Residency, Internal Medicine, 1995 - 1998
University of Maryland School of MedicineClass of 1995

Certifications & Licensure

CA State Medical License 1997 - Present
GA State Medical License 2005 - 2025
MD State Medical License 2000 - 2005
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Start of enrollment: 2004 Aug 01
Terminated
Phase 2, Phase 3
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer Start of enrollment: 2008 Oct 01
Completed
Phase 2
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer Start of enrollment: 2005 May 01
Terminated
Phase 2
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer Start of enrollment: 2006 Jun 01
Terminated
Phase 2
Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD) Start of enrollment: 2011 Apr 01
Completed
Phase 2
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant Start of enrollment: 2010 Dec 01
Completed
Phase 2
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases Start of enrollment: 2011 Apr 01
Completed
Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients Start of enrollment: 2012 Feb 01
Completed
Phase 2
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation Start of enrollment: 2012 Feb 01
Recruiting
Phase 2
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Completed
Phase 2
Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant Start of enrollment: 2016 Sep 28
Completed
Phase 2
SEL24/MEN1703 in Patients With Acute Myeloid Leukemia Start of enrollment: 2017 Mar 10
Completed
Phase 1, Phase 2
Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL Start of enrollment: 2019 Mar 11
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Ibrutinib and Rituxan for Chronic GVHD Start of enrollment: 2019 Dec 16
Terminated
Phase 2
Roles: Principal Investigator, Contact, Sub-Investigator
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Start of enrollment: 2021 Nov 12
Active, not recruiting
Phase 2
Roles: Principal Investigator
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) Start of enrollment: 2016 Jan 06
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2017 Nov 27
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease Start of enrollment: 2024 Jan 29
Recruiting
Phase 2
Roles: Contact, Principal Investigator
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2020 Feb 05
Terminated
Phase 1
Roles: Contact
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant Start of enrollment: 2024 Aug 30
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant Start of enrollment: 2024 Aug 31
Withdrawn
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1193 citations
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang
Lancet. 2020-09-19
81 citations
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a ra...
Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell, Tara L. Lin, Ellen K. Ritchie
The Lancet. Haematology. 2021-07-01
589 citations
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute My...
Jeffrey E. Lancet, Geoffrey L. Uy, Jorge E. Cortes, Laura F. Newell, Tara L. Lin
Journal of Clinical Oncology. 2018-07-19

Abstracts/Posters

Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidentical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Inciden...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
SEL120 _ a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinica...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Improved Survival of Patients Diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 ...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Psychological and Social Factors Are a Strong Predictor of Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Independent of Disease Risk and Mor...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory AnalysisClinically Relevan...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Anal...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase II Trial of Melphalan Based Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hemato...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Reduced Toxicity Conditioning for Non-Malignant Hematopoietic Cell Transplants
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylatin...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...
Scott R. Solomon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Trans...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member